Sign In
Buy COR
$263.64
-1.20 (-0.453%)
At Close: Jun 03, 2026
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
10:21am, Thursday, 28'th Aug 2025
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, HWM, COR and CAKE are some such stocks.
Cencora Appoints Mark Durcan as Chairman of Its Board of Directors
04:15pm, Wednesday, 27'th Aug 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has appointed Lead Independent Director D. Mark Durcan as Chairman of the Board of Directors,
Cencora (COR) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Wednesday, 27'th Aug 2025
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?
10:41am, Wednesday, 20'th Aug 2025
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Why Cencora (COR) is a Top Value Stock for the Long-Term
10:41am, Friday, 15'th Aug 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
02:31pm, Tuesday, 12'th Aug 2025
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x for
3 Reasons Growth Investors Will Love Cencora (COR)
01:46pm, Monday, 11'th Aug 2025
Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy
05:08pm, Friday, 08'th Aug 2025
I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript
12:25pm, Wednesday, 06'th Aug 2025
Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
11:31am, Wednesday, 06'th Aug 2025
Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:31am, Wednesday, 06'th Aug 2025
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Cencora (COR) Q3 Earnings and Revenues Surpass Estimates
08:41am, Wednesday, 06'th Aug 2025
Cencora (COR) came out with quarterly earnings of $4 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $3.34 per share a year ago.
Cencora raises annual profit forecast on strong demand for specialty drugs
07:51am, Wednesday, 06'th Aug 2025
U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped Wall Street estimates, buoyed by surging demand for specialty therapies and bl
Cencora Reports Fiscal 2025 Third Quarter Results
06:30am, Wednesday, 06'th Aug 2025
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2025 third quarter ended June 30, 2025, revenue increased 8.7 percent year-over-year to $80.7 billion. On
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
01:11pm, Monday, 04'th Aug 2025
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
